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Dalbavancin is a lipoglycopeptide antimicrobial agent with a potency significantly better than that of
vancomycin when tested against staphylococci and streptococci. These two pathogens are common causes of
skin and skin structure infections (SSSIs), and dalbavancin has been approved for the treatment of moderate
to severe SSSIs. This study generated susceptibility data for staphylococci and -hemolytic streptococci from
52 U.S. medical centers that locally tested dalbavancin, vancomycin, and other antimicrobial class represen-
tatives to assess the potency of dalbavancin and the overall contemporary activities of commonly prescribed
agents. Locally generated data showed that oxacillin-resistant staphylococci (57.0% overall) had slightly higher
dalbavancin MIC90 values (0.19 g/ml) than oxacillin-susceptible strains (0.125 g/ml). This potency was 8-
to 16-fold greater than that for vancomycin. -Hemolytic streptococci had MIC90 values ranging between
<0.016 and 0.064 g/ml (highest for group B isolates). Levofloxacin, gentamicin, and tetracycline were active
against oxacillin-susceptible staphylococci (82 to 99% susceptible), with lower susceptibility rates seen for the
oxacillin-resistant strains. Linezolid coverage was >98% against staphylococci. Erythromycin resistance was
high for staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for
oxacillin-susceptible and -resistant Staphylococcus aureus, respectively. -Hemolytic streptococci had a 20.2%
erythromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible to
other tested agents. Etest reading errors were apparent and skewed results towards slightly higher dalbavancin
MICs, requiring further education on how to interpret Etest method results for this compound. Current disk
diffusion breakpoint criteria for oxacillin susceptibility for S. aureus showed a very-major-error rate of 2.3%
and only a 0.9% minor-error rate when cefoxitin was used to predict oxacillin susceptibility. Dalbavancin
demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common
causes of SSSI pathogens in this U.S. multicenter study sample.
Dalbavancin is a novel, long-acting lipoglycopeptide antimi-
crobial agent indicated for the treatment of moderate to severe
skin and skin structure infections (SSSIs) caused by gram-
positive organisms (12, 18, 19, 21, 22). The most common and
important gram-positive pathogens that are associated with
SSSIs are Staphylococcus spp. and Streptococcus spp. Of these
two organism groups, staphylococci are much more clinically
significant due to their higher prevalence and their ability to
display an adept resistance profile involving many antimicro-
bial classes. A report from the SENTRY Antimicrobial Sur-
veillance Program during a 7-year period (1998 to 2004)
showed that Staphylococcus aureus was the leading cause of
SSSIs in North America, Latin America, and Europe, with
prevalence rates of 44.6, 33.5, and 37.5%, respectively (20).
Resistance to oxacillin among these collected S. aureus isolates
ranged from 22.8 to 35.9%. This same study (20) also showed
that -hemolytic streptococci accounted for only 2.2 to 4.7% of
SSSIs during that surveillance period, with similar isolation
frequency rates noted for coagulase-negative staphylococci
(CoNS) (2.8 to 5.1%). High staphylococcal prevalence and
elevated oxacillin resistance rates were detected in dalbavancin
clinical trials studying SSSIs. A phase II proof-of-concept study
conducted in the United States showed that S. aureus was the
most commonly isolated pathogen (83%) and had an oxacillin
resistance rate of 38%, which was most similar to the surveil-
lance data generated from the SENTRY Program in the
United States (20, 22). A subsequent larger phase III nonin-
feriority SSSI trial demonstrated that oxacillin-resistant strains
were recovered from 51% of the enrolled patients (12). These
results and those generated from other published reports have
established that staphylococci and streptococci are the princi-
pal causes of cutaneous infections, and that emerging antimi-
crobial resistance among these species requires alternative em-
pirical or directed treatment options.
Dalbavancin has an extremely long elimination half-life and
is administered intravenously at 1 gram on day 1 followed by a
500-mg dose on day 8 (4, 12, 21, 22). This treatment regimen
was shown to be clinically and microbiologically efficacious and
comparable to twice-daily linezolid therapy administered over
a 14-day period (12). Dalbavancin exhibits excellent in vitro
activity against Staphylococcus spp. (MIC90, 0.06 to 0.12 g/
ml), including strains resistant to oxacillin, and has been shown
to be bactericidal without a propensity towards the develop-
ment of resistance during in vitro serial passage studies (15, 17,
19, 23). This compound also has proven activity against staph-
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ylococci that are resistant to other drug classes, including
strains that are (i) macrolide-lincosamide-streptogramin (MLSB)
resistant, (ii) intermediately resistant or tolerant to vancomy-
cin and, (iii) resistant to linezolid or multidrug resistant (24).
Dalbavancin is very potent against -hemolytic streptococci
(MIC90, 0.016 to 0.06 g/ml), which are usually more suscep-
tible to most antimicrobial agents than are staphylococci (2,
15). -Hemolytic streptococci, however, are evolving towards
reduced antimicrobial susceptibility profiles which include re-
sistance to MLSB agents and tetracyclines, and they have de-
veloped tolerance or resistance to some beta-lactam agents,
vancomycin, and fluoroquinolones, although this is rarely seen
at present (3, 8, 11, 25). Dalbavancin has proven activity against
nonindicated strains, which include gram-positive anaerobes
isolated from diabetic foot ulcers and many other important
gram-positive aerobes, including some antimicrobial-resis-
tant strains (10). The U.S. Food and Drug Administration
(FDA) has recently issued dalbavancin a marketable letter.
Susceptible breakpoints have been proposed by the sponsor
for staphylococci at 1 g/ml and for streptococci at 2
g/ml. By utilizing these tentative breakpoints and data gen-
erated by numerous published studies that have assessed the
activity of dalbavancin in multiple geographic regions, it has
been demonstrated that resistance to dalbavancin is extremely
rare and does not readily develop in vitro (15, 17, 19, 23).
The objective of this study was to generate contemporary
(immediately before clinical launch) quantitative MIC suscep-
tibility testing data for dalbavancin and vancomycin (compar-
ator agent), along with the susceptibility profiles of several
other drug classes against staphylococci (oxacillin-susceptible
and -resistant strains) and -hemolytic streptococci. This mul-
ticenter study identified the current susceptibility profiles of
these important pathogens and determined the comparative
activity of dalbavancin tested against nearly 2,500 isolates col-
lected from over 50 leading medical institutions geographically
dispersed throughout the United States prior to the clinical
availability of dalbavancin into clinical or hospital settings.
MATERIALS AND METHODS
Each study site was recruited to test 50 locally collected clinical isolates,
including a targeted number of oxacillin-resistant S. aureus (ORSA) strains (20
isolates), oxacillin-susceptible S. aureus (OSSA) strains, or CoNS (20 isolates)
and -hemolytic streptococci with an emphasis on S. pyogenes strains (10 iso-
lates). A total of 52 sites from 30 states participated in the study (Fig. 1). Each
site tested between 10 and 59 isolates of staphylococci and -hemolytic strepto-
cocci, contributing a total of 2,538 isolate results (97.2% compliance). Among
the tested isolates, 2,490 strains were considered to be valid for analysis after
quality control (QC) results were taken into consideration. These included
ORSA strains (1,009), OSSA strains (762), OR-CoNS (182), OS-CoNS (58), and
-hemolytic streptococci (479; 63.3% S. pyogenes strains). The medical centers
were asked to provide a minimal amount of patient demographic information,
including the sex and age of each patient, the source of infection, and whether
the patient was hospitalized in an intensive care unit. Isolates were collected
from the following specimen sources: skin/skin structure (41%), bloodstream
(28%), respiratory tract (21%), and unknown sources (10%). For sites that sent
demographic data, 58% of patients were male and 42% female, their ages ranged
from 0 to 97 years (median age, 45 years), and nearly 300 patients (12%) were in
the intensive care unit.
At the local site, isolates were tested for susceptibility using Etest (AB BIODISK,
Solna, Sweden) for dalbavancin and vancomycin. Four other antimicrobial
agents were tested against both staphylococci and streptococci by the disk dif-
fusion method on the same Mueller-Hinton agar plate (supplemented with 5%
sheep blood when testing streptococci). These antimicrobials included erythro-
mycin, clindamycin, levofloxacin, and linezolid. Additionally, oxacillin, cefoxitin,
gentamicin, and tetracycline were tested against the Staphylococcus spp., and
ceftriaxone and penicillin were tested against the Streptococcus spp. Oxacillin and
cefoxitin were tested against staphylococci only to differentiate susceptible
(OSSA) and resistant (ORSA) populations of isolates for comparative purposes
for dalbavancin and the other tested agents. Oxacillin-resistant (mecA pheno-
type-positive) strains were defined as those having resistance to oxacillin or
cefoxitin or both. For comparison between disk diffusion test methods of oxacil-
lin and cefoxitin, the latter was utilized as the reference method according to
CLSI guidelines (7). Susceptibility test methods for disk diffusion followed rec-
ommendations from the Clinical and Laboratory Standards Institute (6) and the
manufacturer’s instructions for the Etest (AB BIODISK). Each site was provided
Etest technical guides, including endpoint reading instructions; photographs
FIG. 1. Geographic distribution of laboratories contributing data for the dalbavancin prelaunch susceptibility study. Centers highlighted in red
indicate sites reporting elevated Etest MICs.
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were also provided on how to properly interpret disk approximation with eryth-
romycin (D-test) results (7). Inducible clindamycin resistance was determined by
D-testing as recommended by the CLSI (7). Reported D-test results were de-
termined only on those isolates observed to be erythromycin resistant and sus-
ceptible to clindamycin (ER-CS phenotype). Concurrent QC was performed by
each medical center using S. aureus ATCC 25923 (disk diffusion only), S. aureus
ATCC 29213 (Etests only), and Streptococcus pneumoniae ATCC 49619 for disk
diffusion and Etest reagents. Sites were instructed to perform QC on each day of
testing, and QC failures resulted in the elimination of susceptibility data for that
day and for the affected antimicrobial agent(s). Sites were provided access to a
secure website to download data entry forms which when completed were up-
loaded and transferred to the study coordinator and QC manager (JMI Labo-
ratories, North Liberty, IA) to minimize potential data entry errors.
RESULTS
Table 1 provides the direct MIC comparison of dalbavancin
with vancomycin for the three species groups tested in this
surveillance study. Overall, oxacillin-resistant staphylococci
had slightly higher dalbavancin MICs than oxacillin-susceptible
strains, with MIC90 values of 0.19 and 0.125 g/ml, respec-
tively. The potency of dalbavancin was 8- to 16-fold greater
than that of vancomycin against the staphylococcal strains. All
CoNS isolates were inhibited by 0.25 g/ml of dalbavancin
(100% susceptible using a proposed breakpoint criterion of1
g/ml). However, 1.2% of the ORSA and 1.1% of the OSSA
isolates had dalbavancin MICs of0.38 g/ml and0.5 g/ml,
respectively. It is suspected that many of the Etest MICs re-
corded at 0.19 g/ml may have been erroneously read by
sites that are unfamiliar with the potential reading problems
associated with large-molecular-weight compounds (described
in further detail below). A total of 165 strains (9.3%) of S.
aureus had dalbavancin MICs of0.19 g/ml. A large majority
of these (80.0%) were recorded by only 8 of the 52 participant
laboratories located in geographically diverse areas. Figure 1
shows the locations of the participant sites, and those recording
the higher dalbavancin MICs are highlighted in red. Overall,
dalbavancin was also 16-fold more potent against -hemolytic
streptococci, with a MIC90 of 0.047 g/ml, than vancomycin
(MIC90 of 0.75 g/ml; Table 1).
Variation in the antimicrobial potency of dalbavancin tested
against the five different Lancefield groups of -hemolytic
streptococci was noted (Fig. 2). The MIC90 for group A (S.
FIG. 2. Variations in the antimicrobial activity of dalbavancin tested against different serotypes of -hemolytic streptococci.
TABLE 1. Dalbavancin activity directly compared to that of vancomycin when tested against 2,490 recent (2005 and 2006) gram-positive
isolates from the United States
Organism group
(no. tested)
Antimicrobial
agent
Cumulative % inhibited at indicated MIC (g/ml)a MIC50
(g/ml)b
MIC90
(g/ml)b0.002 0.004 0.008 0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8
S. aureus
Oxacillin-susceptible (762) Dalbavancin 0.0 0.0 0.0 0.0 2.2 57.5 92.0 99.0 100.0 0.064 0.125
Vancomycin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 65.9 100.0 1.0 1.5
Oxacillin-resistant (1,009) Dalbavancin 0.0 0.0 0.0 0.0 2.4 59.0 89.7 98.8 100.0 0.064 0.19
Vancomycin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 61.4 99.8 99.9 100.0 1.0 1.5
Coagulase-negative
staphylococcic
Oxacillin-susceptible (58) Dalbavancin 0.0 0.0 0.0 12.1 31.0 82.8 93.1 100.0 0.047 0.125
Vancomycin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.1 38.7 100.0 1.5 2.0
Oxacillin-resistant (182) Dalbavancin 0.0 0.0 0.0 0.5 13.7 67.0 89.6 100.0 0.064 0.19
Vancomycin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.1 13.1 90.2 100.0 2.0 2.0
-Hemolytic streptococci
(479)d
Dalbavancin 0.2 1.3 8.1 73.5 86.6 98.7 99.8 100.0 0.016 0.047
Vancomycin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.0 86.9 100.0 0.38 0.75
a Etest results (AB BIODISK, Solna, Sweden); results were rounded to log2 scale.
b Etest results unrounded to the log2 scale, allowing MIC precision at the one-half log2 scale (15 total dilution steps).
c CoNS included S. capitis (3 strains), S. epidermidis (59 strains), S. haemolyticus (4 strains), S. hominis (4 strains), S. lugdunensis (4 strains), S. saprophyticus (1 strain),
S. simulans (2 strains), S. warneri (4 strains), and CoNS unidentified to the species level (159 strains).
d -Hemolytic serotypes of streptococci were group A (302 strains), group B (101 strains), group C (26 strains), group F (8 strains), and group G (42 strains).
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pyogenes) strains was 0.016 g/ml, compared with 0.064 g/ml
for group B (S. agalactiae) strains. The remaining serogroups
had MIC90 values ranging between those for the more com-
monly isolated group A and B streptococci and were 0.023
g/ml for group G and 0.032 g/ml for group C. Only eight
group F strains were tested in this study, and dalbavancin was
very potent against them, inhibiting all isolates at MICs of
0.016 g/ml. Variability in the potency of vancomycin tested
against the different groups of -hemolytic streptococci was
minimal (data not shown). The MIC90 values for vancomycin
were 0.5 g/ml, 0.75 g/ml, and 1 g/ml for group G, groups A
and B, and group C, respectively. Serogroup F isolates had a
vancomycin MIC50 result of 0.5 g/ml and a MIC range of 0.19
to 1 g/ml.
Table 2 shows the comparative activities of dalbavancin and
seven other commonly used antimicrobial agents tested against
the 2,490 strains of staphylococci and -hemolytic streptococci.
Although dalbavancin has been shown to be much more potent
than vancomycin, similar breadths of activity were noted for
these antimicrobial agents against all isolates tested. Suscepti-
bility percentages were 100.0% for dalbavancin and ranged
from 99.0 to 100.0% for vancomycin. No vancomycin-resistant
isolates were recovered from this study sample. However, two
strains of ORSA were found that had intermediate vancomycin
MICs of 4 and 8 g/ml (vancomycin-intermediate S. aureus).
The MIC for dalbavancin was only slightly elevated in these
two strains, at 0.25 g/ml. These organisms came from the
same institution in Pennsylvania from different patients, in-
cluding a 47-year-old male with a bloodstream infection and a
58-year-old male with an SSSI. The isolates were unrelated
based upon widely different antibiogram profiles.
The susceptibility profiles for the other antimicrobial classes
varied significantly between the species groups, as did those for
resistance to oxacillin among the staphylococci. ORSA was
very refractory to erythromycin (94.1% resistance), and nearly
one-half (41.7%) of these isolates were also constitutively re-
sistant to clindamycin. The D-test results for inducible clinda-
mycin resistance showed that 26.0% of ER-CS phenotype
ORSA strains were inducibly resistant to clindamycin. Fluoro-
quinolone resistance assay using levofloxacin as a class marker
showed that more than two-thirds (70.3%) of ORSA isolates
were resistant. Resistance to gentamicin and tetracycline was
8%. Two isolates of ORSA, isolated in different hospitals, were
determined to be nonsusceptible to linezolid (MIC,8 g/ml).
Overall, the rate of S. aureus inducible clindamycin resistance
ranged from 0.0 to 78.6% among the medical centers in this
study, with typically higher rates noted for centers in the east-
ern portion of the United States and from some centers in the
Midwest.
Erythromycin resistance among OSSA strains was 30.6%,
with clindamycin resistance at only 5.8%. However, 55.0% of
the ER-CS isolates were shown to be inducibly resistant to
clindamycin. The remaining antimicrobial agents were very
active against these strains, with susceptibility rates of 91.1,
98.7, and 95.1% for levofloxacin, gentamicin, and tetracycline,
respectively. Only one isolate was nonsusceptible to linezolid
among this species group.
The OR-CoNS were also much more resistant to the other
tested agents than were oxacillin-susceptible strains. Erythro-
mycin and clindamycin resistance levels were 81.4 and 53.6%,
respectively, for the oxacillin-resistant strains and 51.6 and
21.0%, respectively, for the oxacillin-susceptible strains. Ap-
proximately 32% of the ER-CS phenotype strains showed in-
ducible clindamycin resistance, regardless of oxacillin suscep-
tibility. Resistance to the other agents was detected for
oxacillin-resistant/oxacillin-susceptible strains at rates of 64.3/
TABLE 2. Dalbavancin activity compared to those of seven other
agents when tested against 2,490 gram-positive coccus isolates
in 52 laboratories by Etest and disk diffusion methods
(United States, 2005 and 2006)
Organism group (no. tested) Antimicrobialagent
% of strains
Susceptiblea Resistantb
S. aureus
Oxacillin-resistant (1,009) Dalbavancin 100.0 -
Vancomycin 99.8 0.0
Erythromycin 5.4 94.1
Clindamycin 55.2 41.7
Levofloxacin 27.7 70.3
Gentamicin 92.0 7.9
Tetracycline 91.8 8.0
Linezolid 99.7 -
Oxacillin-susceptible (762) Dalbavancin 100.0 -
Vancomycin 100.0 0.0
Erythromycin 65.8 30.6
Clindamycin 92.8 5.8
Levofloxacin 91.1 7.6
Gentamicin 98.7 1.3
Tetracycline 95.1 4.4
Linezolid 99.9 -
Coagulase-negative
staphylococcic
Oxacillin-resistant (182) Dalbavancin 100.0 -
Vancomycin 100.0 0.0
Erythromycin 18.6 81.4
Clindamycin 41.5 53.6
Levofloxacin 31.9 64.3
Gentamicin 58.2 35.6
Tetracycline 82.4 16.4
Linezolid 100.0 -
Oxacillin-susceptible (58) Dalbavancin 100.0 -
Vancomycin 100.0 0.0
Erythromycin 45.2 51.6
Clindamycin 79.0 21.0
Levofloxacin 82.3 9.7
Gentamicin 95.0 5.0
Tetracycline 95.0 5.0
Linezolid 98.4 -
-Hemolytic streptococci Dalbavancin 100.0 -
(479)d Vancomycin 100.0 0.0
Penicillin 98.3 -
Ceftriaxone 98.9 -
Erythromycin 76.9 20.2
Clindamycin 87.7 6.0
Levofloxacin 98.7 0.2
Linezolid 99.8 -
a Susceptibility criteria of the CLSI (M100-S16, 2006) were used where avail-
able (7). For dalbavancin, the sponsor-proposed susceptible-only breakpoints of
1 g/ml (staphylococci) and 2 g/ml (streptococci) were used for compari-
sons with vancomycin, with both drugs tested by Etest (AB BIODISK).
b -, no resistance breakpoint criteria have been recommended.
c CoNS included S. capitis (3 strains), S. epidermidis (59 strains), S. haemolyti-
cus (4 strains), S. hominis (4 strains), S. lugdunensis (4 strains), S. saprophyticus
(1 strain), S. simulans (2 strains), S. warneri (4 strains), and CoNS unidentified to
the species level (159 strains).
d -Hemolytic serotypes of streptococci were group A (302 strains), group B
(101 strains), group C (26 strains), group F (eight strains), and group G (42
strains).
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9.7%, 35.6/5.0%, and 16.4/5.0% for levofloxacin, gentamicin,
and tetracycline, respectively. Only one isolate was shown to be
nonsusceptible to linezolid.
The -hemolytic streptococci were very susceptible to the
tested agents, although a 20.2% resistance rate for erythromy-
cin was found, and among the ER-CS phenotypes, a 60.0%
inducible clindamycin resistance rate was observed. Rare
strains showed reproducible nonsusceptible disk zone diame-
ters in response to penicillin, ceftriaxone, levofloxacin, and
linezolid. These strains were considered as the natural extreme
in the distribution of the wild-type susceptible zone diameters,
which were typically only 1 or 2 mm smaller than the CLSI
breakpoint zone.
The CLSI documents have comments that describe the ce-
foxitin disk test as being comparable to the oxacillin disk test
for the prediction of mecA-mediated resistance and indicate
that the cefoxitin disk results are the more easily interpreted
and preferred method (7). Table 3 shows the categorical ac-
curacy of using cefoxitin compared to oxacillin disk tests to
predict mecA-mediated resistance for the S. aureus isolates, as
performed by the local medical centers in this study. A total of
1,761 S. aureus isolates had disk zone diameter results for both
oxacillin and cefoxitin. Using cefoxitin as a surrogate to predict
oxacillin susceptibility resulted in absolute categorical agree-
ment for 96.8% of the strains tested with a very-major-error
(false-susceptible) rate of 2.3%. Only 15 isolates (0.9%) had
oxacillin results that were within the 2-mm intermediate cate-
gory for oxacillin, and 80.0% of these strains were considered
resistant by the cefoxitin disk test. According to the CLSI
recommendations, the cefoxitin disk test, oxacillin MIC test,
oxacillin-salt agar screening test, or molecular methods (mecA
or PBP 2a testing) should be used to report the 15 intermedi-
ate isolates as susceptible or resistant to oxacillin.
Currently, there is no dalbavancin disk diffusion test or an
approved automated system for testing this antimicrobial
agent, although commercial (dry-form) microdilution panels
have been validated (14). One study demonstrated that the use
of currently tested glycopeptides, including vancomycin and
teicoplanin, would accurately characterize the susceptibility to
dalbavancin (16). A study comparing dalbavancin MICs deter-
mined by Etest and reference broth microdilution methods
validated the Etest as an accurate procedure with a very high
level of intermethod agreement (9). However, dalbavancin
MICs obtained with Etest may be falsely elevated due to in-
terpretive errors when reading the ellipse of inhibition. An
image of an Etest result testing dalbavancin against a clinical
isolate of S. aureus is shown in Fig. 3. This figure provides a
visualization of two problematic affects associated with testing
large-molecular-weight compounds (dalbavancin and related
peptide compounds) having compromised diffusion character-
istics in agar media when determining the appropriate MIC.
The ellipse created by dalbavancin tends to become distorted,
with a narrowing effect at concentrations that are near the true
MIC. As demonstrated in the figure, this effect begins at ap-
proximately 0.25 g/ml for this particular strain. According to
manufacturer’s recommendations, results should not be ex-
trapolated from the curvature towards the strip edge. Also,
different intersections on either side of the strip should be read
as the higher MIC (incorrect interpretations are indicated in
Fig. 3). The MIC for this strain should be read at 0.06 g/ml,
which was verified by reference broth microdilution testing (7).
DISCUSSION
This study generated susceptibility data against a large num-
ber of contemporary (2005 and 2006) isolates from numerous
hospitals geographically dispersed throughout the United
States and provided the local laboratories with a test method
with which to determine the potency of a novel lipoglycopep-
tide, dalbavancin, against gram-positive strains isolated in their
community. An approval letter by the FDA has been issued for
dalbavancin for the treatment of moderate to severe SSSI;
susceptibility breakpoints have also been suggested (used
here), and QC ranges have been published by the CLSI (7)
based on studies reported by Anderegg et al. (1). Dalbavancin
FIG. 3. Dalbavancin Etest result tested against a clinical isolate of
S. aureus demonstrating a narrow ellipse with the appropriate MIC
interpretation (arrow without an X). Incorrect interpretations are ar-
rows with X’s.
TABLE 3. Comparison of categorical accuracies for oxacillin and
cefoxitin disk results when 1,761 S. aureus strains were tested
in the dalbavancin in vitro study
Cefoxitin
susceptibility
category
No. of strains (%) in indicated oxacillin susceptibility
category
Susceptible Intermediate Resistant
Susceptible 748 (42.6)a 3 (0.2) 1 (0.1)
Resistant 37 (2.3)b 12 (0.7) 957 (54.2)a
a Absolute categorical agreement was 96.8%, and minor errors were at only
0.9%.
b Assuming cefoxitin results as presented in reference 7, very major (false-
susceptible) errors were noted at 2.3%.
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showed excellent in vitro activity when the Etest (AB BIODISK)
method was utilized against indicated species of staphylococci
(MIC90, 0.125 to 0.19 g/ml) and -hemolytic streptococci
(MIC90, 0.047 g/ml), which are common causes of SSSI. How-
ever, care must be exercised when determining the MICs ob-
tained with Etest, as these MICs may be falsely elevated due to
interpretive errors in reading the narrow inhibitory ellipses
produced by dalbavancin (Fig. 3). This antimicrobial agent was
demonstrated to be 8- to 16-fold more potent than vancomycin
against these pathogens, confirming several earlier studies (15,
17, 23). This study also documented that very high resistance
rates for commonly used agents exist and were particularly
worrisome in regards to oxacillin-resistant staphylococci and
that MLSB resistance was quite high among streptococci. Ce-
foxitin, used as the preferred surrogate disk test marker for
predicting oxacillin susceptibility (6, 7, 26), showed that utiliz-
ing the oxacillin disk result produced very major errors in over
2% of the strains and that only a small number of isolates
(1%) would need confirmation tests due to intermediate
oxacillin disk test categorization (minor error). An investiga-
tion that studied the sensitivities and specificities of the oxacil-
lin and cefoxitin disk test compared to those of the reference
standard (mecA testing) showed similar results for S. aureus,
with 95% sensitivity for both disk tests (26). However, when
tested against CoNS, the cefoxitin disk test was significantly
more accurate than the oxacillin disk test, with sensitivities of
90.5 and 83.4%, respectively (26).
Surveillance studies that have tested large numbers of iso-
lates from worldwide collections indicate that dalbavancin po-
tency data were similar to the data generated here. These
studies tested isolates by use of validated broth microdilution
methods, with MIC90 values that ranged from 0.06 to 0.12
g/ml for staphylococci and 0.016 to 0.03 g/ml for strepto-
cocci (15, 17, 23). Yet another study documented that dalba-
vancin was also very active against antimicrobial-resistant
gram-positive pathogens, demonstrating that dalbavancin sus-
ceptibility was not influenced by staphylococcal strains having
a decreased susceptibility to vancomycin, linezolid, or quinu-
pristin-dalfopristin (24). Dalbavancin is known to be bacteri-
cidal and may provide complete or partial synergy in vitro
when used in combination with other antimicrobial classes
(13).
The recent favorable findings from phase 2 and 3 clinical
trials on the efficacy of dalbavancin against species that cause
SSSI (5, 12, 18, 22), the prolonged elimination half-life, which
allows weekly dosing, and the acceptable safety profile, along
with the activity measurements that have been provided by this
U.S. multicenter trial, all combine to make this antimicrobial
agent a novel treatment alternative in an era of increasing
bacterial resistance.
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